Tumor necrosis factor antagonists and cancer in patients with rheumatoid arthritis: Commentary

Nature Clinical Practice Rheumatology

Volumn 3, Issue 1, 2007, Pages 14-15

  Matteson, Eric L ^a   Bongartz, Tim ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

CANADA; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; COMORBIDITY; DISEASE SEVERITY; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; META ANALYSIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SOLID TUMOR; SYSTEMATIC REVIEW; UNITED STATES; URINARY TRACT CANCER;

EID: 33846978716     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0376     Document Type: Short Survey

References (4)

1. Chakravarty EF et al. (2005) Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 32: 2130-2135
2. Bongartz T et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275-2285
3. Watson KD at al. (2006) Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): Results from the BSR biologics register [abstract]. Ann Rheum Dis 65 (Suppl): S512
4. Askling J et al. (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64: 1421-1426